去铁治疗病例分享PPT参考幻灯片.ppt

* * The safety profile of deferasirox has been well characterized, and most adverse events associated with deferasirox are manageable.The primary adverse events are GI disturbances, including diarrhoea, nausea vomiting, and abdominal pain.1 It has been noted that GI disturbances are the main cause of discontinuation of deferasirox treatment.2 Prompt and effective management of these adverse events may reduce the need for treatment discontinuation, allowing more patients to continue to receive iron chelation therapy. References Gattermann N, et al.Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study.Leuk Res.2010;34:1143-50. Nolte F, et al.Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox.Leuk Res.2011;35:1131-5. Abbreviations GI = gastrointestinal MDS = myelodysplastic syndromes * In the clinical evaluation of deferasirox, gastrointestinal disturbances were seen to be generally mild-to-moderate in s